重视2019冠状病毒病(COVID-19)诱导的脓毒症免疫抑制被引量：15

Pay attention to 2019 coronavirus disease(COVID-19)induced sepsis immunosuppression

在线阅读下载PDF

导出

摘要 2019冠状病毒病(COVID-19)是由SARS-COV-2病毒引起的感染性疾病,缺乏特异的有效治疗措施。COVID-19的临床表现和国内外研究显示,SARS-COV-2引起的病毒性脓毒症具有典型的脓毒症病理生理过程特点,即早期的细胞因子风暴和随后的免疫抑制阶段。目前临床上对细胞因子风暴的治疗和临床研究非常重视,但是忽略了后期的免疫抑制阶段。由于处于该阶段的患者免疫力低下,常出现二次感染、多器官功能衰竭,导致病情迅速恶化甚至死亡。因此,重视COVID-19引起的脓毒症免疫抑制阶段的研究和救治,研究具有双向免疫调节作用的药物如青蒿琥酯对降低COVID-19重症、危重症患者的病死率具有非常重要的意义,强烈建议重症和危重症患者慎用磷酸氯喹。 2019 coronavirus disease(COVID-19)is an infectious disease caused by SARS-COV-2 virus,and lacks specifically effective treatment till now.Its clinical manifestations and the concerning studies at home and abroad have shown that viral sepsis caused by SARS-COV-2 virus has typical characteristics of pathophysiology of sepsis,that is,early cytokine storm and subsequent immunosuppression stage.At present,although great attention has been paid to the treatment and clinical research on cytokine storm,the later stage of immunosuppression is neglected.Patients’lower immunity,secondary infection and multiple organ failure are quite common,and all these lead to rapid deterioration and even death.Therefore,it is of great significance to pay attention to the investigation and treatment of sepsis immunosuppression stage caused by COVID-19,and to study the drugs with bidirectional immune regulation such as artesunate so as order to reduce the mortality of patients with severe or critical COVID-19.What’s more,we strongly recommend that chloroquine phosphate should be used with great caution for severe and critical patients.

作者周红李小丽李斌 ZHOU Hong;LI Xiaoli;LI Bin(Key Laboratory of Basic Pharmacology of Ministry of Education&Joint International Research Laboratory of Ethnomedicine of Ministry of Education,Zunyi Medical University,Zunyi,Guizhou Province,563003;Department of Pharmacology,Faculty of Pharmacy and Laboratory Medicine,Army Medical University(Third Military Medical University),Chongqing,400038;College of Pharmacy,Chongqing Medical University,Chongqing,400016;Department of Pharmacy,Daping Hospital,Army Medical University(Third Military Medical University),Chongqing,400042,China)

机构地区遵义医科大学基础药理教育部重点实验室暨特色民族药教育部国际合作联合实验室陆军军医大学(第三军医大学)药学与检验医学系药理学教研室重庆医科大学药学院陆军军医大学(第三军医大学)大坪医院药剂科

出处《第三军医大学学报》 CAS CSCD 北大核心 2020年第6期539-544,共6页 Journal of Third Military Medical University

基金国家自然科学基金面上项目(81872914,81673495) 国家重大新药创制项目(2017ZX09101002-002-009)。

关键词 COVID-19 脓毒症细胞因子风暴免疫抑制双向免疫调节药青蒿琥酯 COVID-19 sepsis cytokine storm immunosuppression bidirectional immune regulator artesunate

分类号 R563.1 [医药卫生—呼吸系统]

引文网络
相关文献

参考文献1

1周红,刘鑫,郑江.脓毒症治疗--挑战与机遇并存[J].第三军医大学学报,2013,35(2):91-94. 被引量：10

二级参考文献21

1The Lancet. New hope for sepsis[J]. Lancet, 2012, 379(9825): 1462.
2Ranieri V M, Thompson B T, Barie P S, et al. Drotrecogin alfa ( acti- vated) in adults with septic shock[J]. N Engl J Med, 2012, 366 (22) : 2055 -2064.
3Wenzel R P, Edmond M B. Septic shock: evaluating another failed treatment[J]. N Engl J Med, 2012, 366(22) : 2122 -2124.
4Rittirsch D, Flierl M A, Ward P A. Harmful molecular mechanisms in sepsis[J]. Nat Rev Immunol, 2008, 8(10) : 776 -787.
5Hotchkiss R S, Coopersmith C M, McDunn J E, et al. The sepsis see- saw : tilting toward immunosuppression [ J ]. Nat Med, 2009, 15 (5) : 496 - 497.
6Dellinger R P, Levy M M, Carlet J M, et aL Surviving Sepsis Cam- paign: international guidelines for management of severe sepsis and septic shock: 2008[J]. Crit Care Med, 2008, 36( 1 ): 296 -327.
7Casserly B, Gerlach H, Phillips G S, et al. Low-dose steroids in adult septic shock : results of the Surviving Sepsis Campaign [ J ]. Intensive Care Med, 2012, 38(12): 1946-1954.
8Rachoin J S, Schorr C A, Dellinger R P. Targeting endotoxin in the treatment of sepsis[ J ]. Subcell Biochem, 2010 ( 53 ) : 323 - 338.
9Barochia A, Solomon S, Cui X, et al. Eritoran tetrasodium (E5564) treatment for sepsis: review of preelinieal and clinical studies [ J ]. Ex- pert Opin Drug Metab Toxicol, 2011, 7(4) : 479 -494.
10Morris P E, Zeno B, Bernard A C, et al. A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intra- venous infusions of AZD9773 in patients with severe sepsis and septic shock[J]. Crit Care, 2012, 16(1): R31.